The nation of Zimbabwe has turned down a significant American healthcare agreement worth 367 million US dollars (272 million pounds) over five years over Washington's demand for sensitive information.
The decision was revealed following a official document from December was leaked, revealing that Head of State Emmerson Mnangagwa deemed the arrangement was "skewed".
An official spokesperson later clarified that the United States was demanding access to health data for scientific study and profit but was unwilling to guarantee the benefits from future vaccines.
"We will now turn to the challenging and unfortunate task of ending our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had donated more than $1.9bn in health funding to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has urged continued dialogue to find a agreement acceptable to both sides so the nation's critical HIV treatment initiative can proceed.
Wider Implications
Zimbabwe's decision follows a similar case in Kenya, where a court suspended a related health funding agreement after legal challenges were filed about the safety of Kenyans' health data.
Since resuming office recently, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
USAID had administered aid for the American government, but Trump stated its spending was "inefficient" and his administration was pursuing direct bilateral agreements to enhance openness and responsibility.
According to statements, Sixteen nations in Africa have to date agreed to these new agreements, constituting more than $18.3bn in committed funds.
Details of the Rejected Deal
This assistance for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this cooperation would have delivered extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million currently receiving antiretroviral therapy through US-supported programmes," the Ambassador added.
However, government spokesperson Nick Mangwana maintained the arrangement was "unfair".
"The proposal required Zimbabwe to provide its biological resources and data indefinitely, without any equivalent guarantee of access to any scientific breakthroughs – such as new medicines or tests – that might be developed from that shared data," he stated.
"Effectively, our country would provide the basic resources for scientific discovery without any certainty that the resulting innovations would be available to our population if a future disease outbreak emerge."
National Interest and Global Health
Mangwana further said that the American exit from the global health body and its push of one-on-one deals were upending frameworks previously set up through the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme designed to deal with potential global health emergencies.
"This mechanism is intended to guarantee that when a nation contributes its information, the resulting advantages – such as medicines and cures – are shared equitably, not commercialised solely by those with the funds to create them."
These objections regarding the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We welcome ongoing dialogue with our US partners on how future collaboration could be designed in a manner that honours the sovereignty and interests of both nations."
Medical Community Reaction
A leading public health body said it recognised the official position, but recommended that negotiations must proceed considering a large portion of the country's HIV programmes were funded by external financing.
"If specific concerns arise, including those involving data governance or implementation frameworks, these can frequently be addressed via detailed discussion and negotiated safeguards," it added.
This impasse underscores the continuing debate between accepting vital foreign assistance and safeguarding national sovereignty in an increasingly data-driven world.